Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours.
CONCLUSIONS: Belinostat is well tolerated in both patient groups and shows some activity in patients with micropapillary (LMP) disease.
An ovarian cancer blog which includes quality resource materials: education, research, social networking, genetics and (some) healthcare politics.
“Not everything that can be counted counts and not everything that counts can be counted.”
Albert Einstein
No comments:
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.